Dignity Therapy in mCRC to Increase Peaceful Awareness & Impact Goals of Care Decision-Making



Status:Completed
Conditions:Colorectal Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/30/2013
Start Date:April 2010
End Date:April 2015
Contact:Max Vergo, MD
Email:mvergo@nmff.org
Phone:312-695-6180

Use our guide to learn which trials are right for you!

Use of Dignity Therapy in Stage IV Colorectal Cancer Patients Receiving Chemotherapy to Increase Peaceful Awareness and Impact Goals of Care Decision-Making


The purpose of this study is to try and improve the way that patients with colon cancer
understand and cope with their illness and give them tools for talking with their loved ones
and family about their illness.


Dignity Therapy is a well tolerated structured interview that helps patients reflect on who
they are, what is most important to them and what lessons they have learned through life.
For patients not receiving chemotherapy, Dignity Therapy gave patients more hope, more
meaning in their life, and helped their families. Researchers at Northwestern University
would like to see if it has the same effect in patients getting chemotherapy. We will also
see if the Dignity Therapy changes patient's understanding of their disease and their
medical preferences.

All study procedures will take place when participants come for a scheduled doctor's visit
or to receive chemotherapy. At the first visit participants will answer a questionnaire
taking approximately 15-30 minutes. Participants will then have a Dignity Therapy Session
approximately 1-2 weeks later. A second Dignity Therapy Session will be scheduled again in
another 1-2 weeks. Each study Dignity Therapy Session will take approximately an hour. One
to two weeks later a repeat questionnaire will be filled out. Finally, a third and final
questionnaire will be complete 4 weeks later.

Inclusion Criteria:

- Participants must be currently receiving treatment for stage IV colorectal cancer.

- Participants must have experience disease progression after their first course of
treatment and are being considered for second course of treatment or have already
started their second course of treatment.

- Participants must be 18 years old or older.

- All participants must have given signed, informed consent prior to registration on
study.

- Participants must speak English.

Exclusion Criteria:

-
We found this trial at
1
site
?
mi
from
Chicago, IL
Click here to add this to my saved trials